In vitro diagnostic companies bagged last year's top revenue, net profit

Eastern Money Choice data shows that as of April 13, 28 listed companies in the medical device category have disclosed their 2022 annual reports, of which 18 companies have achieved year-on-year growth in net profit, accounting for 64.29%. From the perspective of specific segments, the overall performance of in vitro diagnostic companies is impressive.

So far, among the 28 medical device companies that have disclosed last year's annual report, two companies have net profit growth rates of more than 100%, both in the field of in vitro diagnostics (IVD).

Blood glucose meter leader Sinocare’s net profit growth rate topped the list. 2022, Sinocare achieved net profit of 431 million yuan, up 300.56% year-on-year.

HPV vaccine leader Wantai BioPharm's net profit growth rate followed. In 2022, the company achieved net profit of 4.736 billion yuan, up 134.28% year-on-year.

In terms of revenue, three companies are located in the 10 billion yuan echelon, namely Dian Diagnostics, Daan Gene and Wantai BioPharm, all of which are IVD companies. During the reporting period, revenue of Dian Diagnostics reached 20.282 billion yuan, up 55.03% year-on-year; revenue of Daan Gene reached 12.046 billion yuan, up 57.17% year-on-year; revenue of Wantai BioPharm reached 11.185 billion yuan, up 94.51% year-on-year.